Details:

Alternative Title:
Cancer
Publisher's site:
http://dx.doi.org/10.1002/cncr.30322
Personal Author:
Muffly, Lori ; Lichtensztajn, Daphne ; Shiraz, Parveen ; Abrahão, Renata ; McNeer, Jennifer ; ... More +
Muffly, Lori ; Lichtensztajn, Daphne ; Shiraz, Parveen ; Abrahão, Renata ; McNeer, Jennifer ; Stock, Wendy ; Keegan, Theresa ; Gomez, Scarlett Lin Less -
Description:
Background

Studies show superior outcomes for adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) treated following pediatric versus adult ALL therapeutic regimens. Whether adult oncologists in the United States have adopted this approach to AYA ALL is currently unknown. We sought to provide a population-based description of AYA ALL treatment patterns over the past decade.

Methods

Data on AYAs 15-39 years and diagnosed with ALL during 2004-2014 while living in the Greater Bay Area were obtained from the Greater Bay Area Cancer Registry (GBACR). Treating facilities were designated as pediatric or adult centers; induction treatment regimens were abstracted from registry text data fields.

Results

Of 304 patients diagnosed in the GBACR catchment region, complete treatment data was available for 229 (75%). Location of care was identified for 296 (97%) patients treated at 31 unique centers. 70% of AYAs received induction therapy at an adult center. All AYAs treated at pediatric centers received pediatric ALL regimens. Among AYAs treated by adult oncologists with complete treatment data, none received a pediatric regimen prior to 2008. From 2008-2012, while the adult intergroup C10403 pediatric-inspired ALL protocol was open to accrual, 31% of AYAs treated by adult oncologists received pediatric regimens. This fell to 21% in 2013-2014. Adult facilities treating ≥2 AYA ALL GBACR patients per year were more likely to administer pediatric regimens than lower volume centers (P= 0.03).

Conclusion

As of 2014, only a minority of AYAs with ALL received pediatric ALL regimens at adult cancer centers.


Subject:
[+]
Adolescent Adult Antineoplastic Agents Female Humans Male Oncologists Precursor Cell Lymphoblastic Leukemia-Lymphoma Young Adult
Source:
Cancer. 123(1):122-130.
Pubmed ID:
27622953
Pubmed Central ID:
PMC5161602
Document Type:
Journal Article
Funding:
HHSN261201000035C/PC,CA/None/None ; HHSN261201000140C/CA/NCI NIH HHS/United States ; HHSN261201000036C/CA/NCI NIH HHS/United States ; HHSN261201000035I/CA/NCI NIH HHS/United States ; HHSN261201000034C/CA/NCI NIH HHS/United States ; ... More +
HHSN261201000035C/PC,CA/None/None ; HHSN261201000140C/CA/NCI NIH HHS/United States ; HHSN261201000036C/CA/NCI NIH HHS/United States ; HHSN261201000035I/CA/NCI NIH HHS/United States ; HHSN261201000034C/CA/NCI NIH HHS/United States ; U58 DP003862/DP/NCCDPHP CDC HHS/United States ; P30 CA124435/CA/NCI NIH HHS/United States Less -
Place as Subject:
United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:c536f556acb4325988734eb5006d1d35f0d0ade2481f55e6fab0b074ba50436e
Download URL:
https://stacks.cdc.gov/view/cdc/50675/cdc_50675_DS1.pdf
File Type:

Supporting Files

• 	nihms811779.nxml	xml
  	nihms811779f1.gif	gif
  	nihms811779f1.jpg	jpeg
  	nihms811779f2.gif	gif
  	nihms811779f2.jpg	jpeg

More +